Back to top
more

Gemphire Therapeutics Inc. (GEMP)

(Delayed Data from NSDQ)

$1.27 USD

1.27
9,008

+0.06 (4.96%)

Updated May 3, 2019 03:58 PM ET

After-Market: $1.23 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

M&A, Innovation & New Drugs to Drive Pharma Stocks

The new tax law, which cuts the corporate tax rate from 35% to 21% and encourages companies to bring back cash held overseas at a one-time tax rate of 10%, is expected to spur merger activity.

    AVEO Pharmaceuticals' (AVEO) Q4 Earnings: What's in Store?

    AVEO Pharmaceuticals (AVEO) launched its first drug, Fotivda, as first-line treatment for RCC in Europe in November. This is likely to have a favorable impact on fourth-quarter results.

      What's in the Cards for Inovio (INO) This Earnings Season?

      Inovio's (INO) most advanced pipeline candidate, VGX-3100's consistent progress might drive the stock in Q4. However, lack of an approved product in the company's portfolio is a dampener.

        What's in the Cards for Arena (ARNA) This Earnings Season?

        Although Arena's (ARNA) only approved product, Belviq, has an unimpressive show so far, the company's efforts to improve the drug's performance might drive the stock in Q4.

          What's in the Cards for Merck KGaA (MKGAF) in Q4 Earnings?

          Merck's (MKGAF) Healthcare and Life Science segments are likely to drive sales in Q4. However, the company's oncology drug fails in a phase III gastric cancer study.

            What's in Store for Conatus (CNAT) This Earnings Season?

            Conatus' (CNAT) progress with lead candidate emricasan might boost the stock in Q4. However, the company's portfolio lacks an approved product and its revenue generation.

              What's in Store for Catalyst (CPRX) This Earnings Season?

              Investors focus will be on pipeline and regulatory updates during Catalyst's (CPRX) fourth-quarter earnings call.

                Is a Beat in the Cards for Celldex (CLDX) in Q4 Earnings?

                With no approved product in Celldex Therapeutics' (CLDX) portfolio, investor focus is on immuno-oncology pipeline.

                  What's in the Cards for BioDelivery (BDSI) in Q4 Earnings?

                  BioDelivery's (BDSI) lead drugs Belbuca and Bunavail look promising to deliver an earnings beat in Q4.

                    What's in Store for Epizyme (EPZM) This Earnings Season?

                    Epizyme is expected to provide updates on the development of its pipeline candidates during Q4 earnings call.

                      What's in the Cards for Immune Design (IMDZ) in Q4 Earnings?

                      We expect Immune Design (IMDZ) to shed light on the progression of the trails on pipeline candidates when it releases fourth-quarter earnings results on Mar 6.

                        What's in Store for Intrexon (XON) This Earnings Season?

                        Investor focus are likely to remain on Intrexon's (XON) performance along with other developmental updates during the quarterly call.

                          Madrigal (MDGL) Q4 Earnings: What's in Store for the Stock?

                          Madrigal (MDGL) has no approved product in its portfolio. So, investors' complete focus on fourth-quarter earnings call will be revolving around the company's lead pipeline candidate, MGL-3196.

                            What's in the Cards for Puma (PBYI) This Earnings Season?

                            Contrary to nominal sales generated by Puma's (PBYI) only marketed drug Nerlynx last quarter, post its launch in August 2017, the candidate is likely to fetch higher revenues in Q4.

                              Is a Beat in Store for Adverum (ADVM) This Earnings Season?

                              Adverum Biotechnologies (ADVM) will report its fourth-quarter results in early March. Investors focus is expected to be on pipeline updates.

                                Radius Health (RDUS) to Disappoint Investors in Q4 Earnings?

                                Investors are expected to focus on the uptake of the lead drug, Tymlos when Radius Health (RDUS) reports its fourth-quarter results.

                                  Is a Beat in Store for Horizon Pharma (HZNP) in Q4 Earnings?

                                  On Horizon Pharma's (HZNP) fourth-quarter 2017 earnings call, investors focus will be on the performance of its business units and key products.

                                    What's in the Cards for Merrimack (MACK) in Q4 Earnings?

                                    Investors are likely to remain focused on Merrimack's (MACK) pipeline updates when it reports Q4 numbers, early next month.

                                      What's in Store for Endocyte (ECYT) This Earnings Season?

                                      Endocyte (ECTY) is expected to provide updates on its pipeline candidates EC1169 and EC2629 during the fourth quarter 2017 earnings call on Feb 26.

                                        Can Rhopressa's Approval Drive Aerie (AERI) in Q4 Earnings?

                                        Aerie (AERI) looks poised for a beat when it reports Q4 results (due on Feb 28) on the back of lead drug Rhopressa's approval.

                                          What's in the Cards for Ionis (IONS) This Earnings Season?

                                          Ionis Pharmaceuticals (IONS) earns $70 million in milestone and license payments from several drug companies. Spinraza witnesses strong fourth quarter as announced by Biogen in its earnings release.

                                            Is a Beat in the Cards for Perrigo (PRGO) in Q4 Earnings?

                                            Perrigo's (PRGO) product purchases and launches in the Rx segment might boost sales in the coming quarters.

                                              Jazz Pharmaceuticals (JAZZ) Q4 Earnings: What to Expect?

                                              In Q4, we expect investors' focus on Xyrem's performance, Jazz Pharmaceuticals' (JAZZ) lead product for excessive daytime sleepiness. Also, hopes will be pinned on the company's pipeline progress.

                                                Will Cabometyx Fuel Exelixis' (EXEL) Earnings in Q4 Again?

                                                Exelixis (EXEL) is likely to beat on earnings in the fourth quarter (results due on Feb 26) driven by growth in Cabometyx sales.

                                                  What's in Store for Agenus (AGEN) This Earnings Season?

                                                  Agenus (AGEN) is expected to provide updates on pipeline candidates when it reports Q4 numbers on Mar 8.